Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3993743> ?p ?o }
Showing triples 1 to 44 of
44
with 100 triples per page.
- Q3993743 subject Q7297892.
- Q3993743 subject Q8728165.
- Q3993743 subject Q8965786.
- Q3993743 abstract "Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.In 2007 the pharmaceutical company GTx, Inc was conducting two different phase 3 clinical trials; First, a pivotal Phase clinical trial for the treatment of serious side effects of androgen deprivation therapy (ADT) (especially vertebral/spine fractures and hot flashes, lipid profile, and gynecomastia) for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. Results of these trials are expected by first quarter of 2008An NDA for the first application (relief of prostate cancer ADT side effects) was submitted in Feb 2009, and in Oct 2009 the FDA said they would need more clinical data, e.g. another phase III trial.".
- Q3993743 atcPrefix "L02".
- Q3993743 atcSuffix "BA02".
- Q3993743 casNumber "89778-26-7".
- Q3993743 chEBI "9635".
- Q3993743 drugbank "DB00539".
- Q3993743 fdaUniiCode "7NFE54O27T".
- Q3993743 iupacName "2-{4-[(1Z)-4-chloro-1,2-diphenyl-but-1-en-1-yl]phenoxy}-N,N-dimethylethanamine".
- Q3993743 pubchem "3005573".
- Q3993743 thumbnail Toremifene.svg?width=300.
- Q3993743 wikiPageWikiLink Q128581.
- Q3993743 wikiPageWikiLink Q15731388.
- Q3993743 wikiPageWikiLink Q181257.
- Q3993743 wikiPageWikiLink Q181876.
- Q3993743 wikiPageWikiLink Q1858291.
- Q3993743 wikiPageWikiLink Q204711.
- Q3993743 wikiPageWikiLink Q277954.
- Q3993743 wikiPageWikiLink Q30612.
- Q3993743 wikiPageWikiLink Q339221.
- Q3993743 wikiPageWikiLink Q4759439.
- Q3993743 wikiPageWikiLink Q5514784.
- Q3993743 wikiPageWikiLink Q7297892.
- Q3993743 wikiPageWikiLink Q8728165.
- Q3993743 wikiPageWikiLink Q8965786.
- Q3993743 wikiPageWikiLink Q903917.
- Q3993743 atcPrefix "L02".
- Q3993743 atcSuffix "BA02".
- Q3993743 casNumber "89778".
- Q3993743 chebi "9635".
- Q3993743 drugbank "DB00539".
- Q3993743 iupacName "2".
- Q3993743 pubchem "3005573".
- Q3993743 unii "7".
- Q3993743 type ChemicalSubstance.
- Q3993743 type Drug.
- Q3993743 type ChemicalObject.
- Q3993743 type Thing.
- Q3993743 type Q8386.
- Q3993743 comment "Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer.".
- Q3993743 label "Toremifene".
- Q3993743 depiction Toremifene.svg.